Health Technology Assessment (HTA), the process used to evaluate the value of medicines, vaccines, devices and digital tools, is undergoing a major shift. Once viewed mainly as a reimbursement gatekeeper, HTA is now a framework that guides how organizations across biopharma, biotech, and academia, generate evidence and assess the value of new technologies as health system priorities evolve. A one-time evaluation at product launch has become a continuous, multidimensional process that rewards early preparation, stronger data collection, and deeper engagement with stakeholders.
This report outlines 10 key trends we are seeing that leaders across biopharma, global health, and public agencies need to understand as HTA enters a new era. As global markets grow more complex and innovation accelerates, organizations that anticipate these changes will be best positioned to deliver value for both patients and payers.
Download the Report
The Future of HTA: Key Trends and Strategic Implications for 2026 and Beyond examines the decisive shift of HTA from a downstream compliance exercise to a strategic framework, outlining 10 key trends organizations must navigate to demonstrate value and secure access in a new era of healthcare.